Ranked by published formula, not vibes
Best GLP-1 Providers of 2026, Ranked
All 23 priced programs we track, scored on a published 100-point formula: price 45, price evidence 15, pharmacy disclosure 10, flexibility 15, breadth 15. NexLife leads at 90.0/100.
“Best” is where comparison sites usually hide their sponsors, so ours is arithmetic you can check: forty-five points for all-in price against the market floor, fifteen for how well the price is evidenced, ten for naming the pharmacy that actually compounds the medication, fifteen for flexibility (commitment and cancellation terms), and fifteen for breadth (both molecules, brand access, insurance help). The formula lives on our methodology page; the inputs live in the downloadable dataset; change either and you can reproduce or re-rank this list yourself. What the score deliberately cannot see: your dose, your state, your insurance, and your risk tolerance for compounded medication — which is why every entry carries its conditions in the sentence, not a footnote.
Composite score 90.0/100 on our published formula. Tirzepatide: $215 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $186/mo (12-month plan). Semaglutide runs $165 a month all-in at the standing rate ($145 on intro/plan terms). Names its dispensing pharmacy.
Composite score 80.0/100 on our published formula. Semaglutide runs $133 a month all-in.
Composite score 79.8/100 on our published formula. Tirzepatide: $278 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, including the mandatory $79/mo membership. Semaglutide runs $178 a month all-in. Names its dispensing pharmacy.
Composite score 71.1/100 on our published formula. Semaglutide runs $199 a month all-in — capped at 0.6 mg, a quarter of the trial dose. Names its dispensing pharmacy.
Composite score 68.5/100 on our published formula. Tirzepatide: $289 a month all-in at the 10 mg maintenance basis, dose-scaled from a $199 entry, no membership fee. Semaglutide runs $249 a month all-in at the standing rate ($175 on intro/plan terms).
Composite score 68.5/100 on our published formula. Tirzepatide: $449 a month all-in at the 10 mg maintenance basis, dose-scaled from a $299 entry, no membership fee. Brand-name fulfillment. Names its dispensing pharmacy.
Composite score 67.5/100 on our published formula. Tirzepatide: $258 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $225/mo (6-month plan). Semaglutide runs $146 a month all-in.
Composite score 67.5/100 on our published formula. Tirzepatide: $289 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $169/mo (12-month plan paid up front). Semaglutide runs $289 a month all-in at the standing rate ($169 on intro/plan terms).
Composite score 65.8/100 on our published formula. Tirzepatide: $278 a month all-in at the 10 mg maintenance basis, dose-scaled from a $208 entry, including the mandatory $75/mo membership. Semaglutide runs $224 a month all-in at the standing rate ($149 on intro/plan terms).
Composite score 64.1/100 on our published formula. Semaglutide runs $349 a month all-in at the standing rate ($199 on intro/plan terms). Brand-name fulfillment. Names its dispensing pharmacy.
Composite score 63.4/100 on our published formula. Tirzepatide: $299 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Semaglutide runs $199 a month all-in.
Composite score 59.5/100 on our published formula. Tirzepatide: $352 a month all-in at the 10 mg maintenance basis, dose-scaled from a $200 entry, including the mandatory $25/mo membership. Semaglutide runs $199 a month all-in at the standing rate ($174 on intro/plan terms).
Composite score 57.7/100 on our published formula. Tirzepatide: $349 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $293/mo (12-month plan). Semaglutide runs $299 a month all-in at the standing rate ($179 on intro/plan terms).
Composite score 54.7/100 on our published formula. Tirzepatide: $408 a month all-in at the 10 mg maintenance basis, dose-scaled from a $348 entry, including the mandatory $99/mo membership. Semaglutide runs $198 a month all-in.
The fine print on “best”
Price dominates the formula on purpose — in a market selling the same molecules, paying $180/month more for a logo is rarely rational — but the non-price points are where the interesting movement happens: programs like Mochi climb on pharmacy ownership and flat all-in pricing despite a mid-pack rate, while third-party-evidenced programs bleed points until we can verify their figures at the source. Brand-fulfillment programs (Ro, WeightWatchers Clinic) score on breadth and insurance navigation rather than cash price, and unpriced programs don't appear at all: a program that publishes no price can't be “best” at anything measurable.
The market, in four load-bearing numbers
The floor and the ceiling: NexLife’s $215 flat all-in against LifeMD’s $597 split-billed — $4,584 a year apart for the identical 10 mg basis, which is the whole argument for normalization. Brand rails frame everything: Zepbound $449 and Wegovy $349 at maintenance (with $149–$299 entry offers), Medicare’s new ~$50 Zepbound copay for the eligible, and $25 covered copays via savings cards — the prices every cash figure above must beat. Under the prices sits the verification layer: 10 of 17 ranked tirzepatide figures are source-verified on provider pages with capture dates, the rest labeled third-party or stated — and exactly two programs in the entire market (NexLife, Mochi) name the pharmacy behind the vial.
How to use this page without getting played
Treat every entry as a claim plus its receipts: the price, its basis (all-in, 10 mg, standing), its date, and its evidence tier travel together here — quote them together too. Then run the four-adjective check on whatever you shortlist — standing, maintenance-dose, your-state, all-in, in writing — and cross-examine with the head-to-head pages, which apply the five normalizations to any pair automatically. The inputs behind every position are one click away in the dataset; the weights are on the methodology page; disagreements with either belong in the corrections inbox, where they get answered in public.
Frequently asked
What is the best GLP-1 provider in 2026?
On our published 100-point formula, NexLife ranks first at 90.0/100 — $215/mo all-in, source-verified, no membership, flat at every dose, with a named pharmacy network. The full formula and inputs are public, so you can re-rank by your own weights.
Is the ranking sponsored?
No placement is paid, and the ranking is computed from the dataset by a published formula — see the editorial policy and ownership disclosure. If a financial relationship exists with any listed company it is disclosed there and does not enter the formula.
Why isn't a well-known brand at #1?
Fame correlates with marketing budgets, not price or transparency. Several famous programs publish no compounded pricing at all (they've moved to brand-only fulfillment) and therefore can't outrank programs with verified, low, all-in figures.